ImmuPharma (LON:IMM) Trading Down 3.5% - What's Next?

Key Points

• ImmuPharma plc shares fell 3.5% on Wednesday, trading as low as GBX 10.58 ($0.14) and last at GBX 11.67 ($0.16), with a total of 8,030,504 shares changing hands.
• The company reported negative earnings per share of GBX (0.38) for the last quarter, and analysts expect a further decline to around -339.00 EPS for the current fiscal year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its leading program, Lupuzor™, being a novel treatment for Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 3.5% on Wednesday . The company traded as low as GBX 10.58 ($0.14) and last traded at GBX 11.67 ($0.16). 8,030,504 shares traded hands during trading, a decline of 6% from the average session volume of 8,560,709 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Stock Performance

The company has a 50-day simple moving average of GBX 4.66 and a 200-day simple moving average of GBX 3.39. The stock has a market cap of £58.47 million, a P/E ratio of -1,314.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.